Sponsor Pipeline

National Cancer Center, China Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
5
Active Trials
1
Recruiting
3
Disease Areas
1
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-02 NCT06362980
A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients…		 overall status: Recruiting → Unknown
Active Trials by Phase
Phase 2
2
Phase 1/2
1
Not specified
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06414915 Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine… NSCLC Not Yet Recruiting
NCT06827145 Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation… Non-Small-Cell Lung Cancer Active, Not Recruiting
Phase 1/2
NCT07131345 Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma Malignant Mesothelioma Not Yet Recruiting
Not specified
NCT06279299 Lateral Pelvic Lymph Node Dissection for Rectal Neuroendocrine Neoplasms Undergoing… Rectal Neuroendocrine Neoplasm Recruiting
NCT06694129 Real-world Observational Study of Targeted Therapy in Patients With Advanced… Non-Small Cell Lung Cancer Not Yet Recruiting
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (3) Lung Cancer (2) Mesothelioma (1)
Get alerts when National Cancer Center, China's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free